More importantly, we screened out a small molecule HIF-2α inhibitor that synergizes with PTX for inhibition of tumor growth in vitro and in vivo, and represents a promising candidate for targeted therapy of breast cancer. The gene discussed is EPAS1; the disease is neoplasm.